Analysts think TBPH stock price could increase by 42%
Oct 08, 2025, 11:25 AM
3.55%
What does TBPH do
Theravance Biopharma, based in Grand Cayman, focuses on developing respiratory medicines and has 99 employees; its key product, YUPELRI, treats COPD. The company is also developing Ampreloxetine for neurogenic orthostatic hypotension and TD-8954 for gastrointestinal motility disorders.
8 analysts think TBPH stock price will increase by 42.16%. The current median analyst target is $20.40 compared to a current stock price of $14.35. The lowest analysts target is $13.13 and the highest analyst target is $29.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.